224 related articles for article (PubMed ID: 27033194)
1. ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders.
Chong CM; Ai N; Lee SM
Curr Drug Targets; 2017; 18(4):455-462. PubMed ID: 27033194
[TBL] [Abstract][Full Text] [Related]
2. ROCK inhibition in models of neurodegeneration and its potential for clinical translation.
Koch JC; Tatenhorst L; Roser AE; Saal KA; Tönges L; Lingor P
Pharmacol Ther; 2018 Sep; 189():1-21. PubMed ID: 29621594
[TBL] [Abstract][Full Text] [Related]
3. Distinct Roles of ROCK1 and ROCK2 on the Cerebral Ischemia Injury and Subsequently Neurodegenerative Changes.
Lu W; Wen J; Chen Z
Pharmacology; 2020; 105(1-2):3-8. PubMed ID: 31537002
[TBL] [Abstract][Full Text] [Related]
4. Emerging targets in drug discovery against neurodegenerative diseases: Control of synapsis disfunction by the RhoA/ROCK pathway.
Martín-Cámara O; Cores Á; López-Alvarado P; Menéndez JC
Eur J Med Chem; 2021 Dec; 225():113742. PubMed ID: 34388381
[TBL] [Abstract][Full Text] [Related]
5. Activation of Rho kinase isoforms in lung endothelial cells during inflammation.
Mong PY; Wang Q
J Immunol; 2009 Feb; 182(4):2385-94. PubMed ID: 19201893
[TBL] [Abstract][Full Text] [Related]
6. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
Knipe RS; Tager AM; Liao JK
Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
[TBL] [Abstract][Full Text] [Related]
7. Novel Insights into the Roles of Rho Kinase in Cancer.
Wei L; Surma M; Shi S; Lambert-Cheatham N; Shi J
Arch Immunol Ther Exp (Warsz); 2016 Aug; 64(4):259-78. PubMed ID: 26725045
[TBL] [Abstract][Full Text] [Related]
8. Role of Rho Kinase and Fasudil on Synaptic Plasticity in Multiple Sclerosis.
Chen C; Yu JZ; Zhang Q; Zhao YF; Liu CY; Li YH; Yang WF; Ma CG; Xiao BG
Neuromolecular Med; 2015 Dec; 17(4):454-65. PubMed ID: 26481340
[TBL] [Abstract][Full Text] [Related]
9. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
Shimokawa H; Satoh K
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233
[TBL] [Abstract][Full Text] [Related]
10. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
[TBL] [Abstract][Full Text] [Related]
11. Rho kinase in the regulation of cell death and survival.
Shi J; Wei L
Arch Immunol Ther Exp (Warsz); 2007; 55(2):61-75. PubMed ID: 17347801
[TBL] [Abstract][Full Text] [Related]
12. The Physiology, Pathology, and Therapeutic Interventions for ROCK Isoforms in Diabetic Kidney Disease.
Matoba K; Takeda Y; Nagai Y; Sekiguchi K; Yokota T; Utsunomiya K; Nishimura R
Front Pharmacol; 2020; 11():585633. PubMed ID: 33101039
[TBL] [Abstract][Full Text] [Related]
13. Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma.
Raad M; El Tal T; Gul R; Mondello S; Zhang Z; Boustany RM; Guingab J; Wang KK; Kobeissy F
Electrophoresis; 2012 Dec; 33(24):3659-68. PubMed ID: 23161464
[TBL] [Abstract][Full Text] [Related]
14. Targeting ROCK signaling in health, malignant and non-malignant diseases.
Shahbazi R; Baradaran B; Khordadmehr M; Safaei S; Baghbanzadeh A; Jigari F; Ezzati H
Immunol Lett; 2020 Mar; 219():15-26. PubMed ID: 31904392
[TBL] [Abstract][Full Text] [Related]
15. Rho kinase inhibitors: a patent review (2012 - 2013).
Feng Y; LoGrasso PV
Expert Opin Ther Pat; 2014 Mar; 24(3):295-307. PubMed ID: 24283930
[TBL] [Abstract][Full Text] [Related]
16. Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders?
Chen M; Liu A; Ouyang Y; Huang Y; Chao X; Pi R
Expert Opin Investig Drugs; 2013 Apr; 22(4):537-50. PubMed ID: 23461757
[TBL] [Abstract][Full Text] [Related]
17. Enhanced neurite outgrowth of human model (NT2) neurons by small-molecule inhibitors of Rho/ROCK signaling.
Roloff F; Scheiblich H; Dewitz C; Dempewolf S; Stern M; Bicker G
PLoS One; 2015; 10(2):e0118536. PubMed ID: 25714396
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.
Kubo T; Yamaguchi A; Iwata N; Yamashita T
Ther Clin Risk Manag; 2008 Jun; 4(3):605-15. PubMed ID: 18827856
[TBL] [Abstract][Full Text] [Related]
19. Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.
Pan P; Shen M; Yu H; Li Y; Li D; Hou T
Drug Discov Today; 2013 Dec; 18(23-24):1323-33. PubMed ID: 24076262
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo.
Lingor P; Teusch N; Schwarz K; Mueller R; Mack H; Bähr M; Mueller BK
J Neurochem; 2007 Oct; 103(1):181-9. PubMed ID: 17608642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
